42 METABOLIC ACTIVATION OF INDUSTRIAL CHEMICALS is excreted in urine. In man and dog the urine is slightly acidic, while in rat and mouse it is slightly alkaline. Under acidic conditions the glucuronide is hydrolyzed to generate the hydroxylamine in the bladder. In this case glucuronidation is not a bioactivation, but rather a targeting biotransformation: in man and dog the carcinogenic metabolite is targeted to the bladder, due to the (necessary!) acidic local pH (Kadlubar et al., 1981). Conclusions The above illustrates the importance <strong>of</strong> bioactivation in toxicity <strong>of</strong> industrial chemicals. Is it possible to predict bioactivation from the structure? As outlined above, in some cases the compound contains structural elements which make bioactivation to a reactive intermediate quite likely. Whether it does play a role in toxicity then is still uncertain. Test systems to detect reactive intermediates depend on, for example, the availability <strong>of</strong> the radiolabeled compound; in fact, a very high specific radioactivity is required to detect low levels <strong>of</strong> binding. Alternatively, radiolabelled glutathione can be used for those reactive intermediates that readily bind to the thiol group <strong>of</strong> glutathione (Mulder and Le, 1988). Whether such systems can pick up every relevant toxic reactive intermediate remains to be seen. For extrapolation <strong>of</strong> one species to the other it is important to have insight into the metabolite that is responsible for the toxicity. Therefore, it is more than just <strong>of</strong> academic interest to know the mechanism <strong>of</strong> toxicity in safety assessment <strong>of</strong> industrial chemicals. Unfortunately, it is <strong>of</strong>ten not easy to establish such a mechanism beyond reasonable doubt: it may require too many rats to feel comfortable about it if we would have to do this for every chemical used industrially! References ANDERS, M.W. (Ed.), 1985, Bioactivation <strong>of</strong> Foreign <strong>Compounds</strong>, Orlando, FL: Academic Press. ANDERS, M.W. and DEKANT, W., 1994, Conjugation-dependent Carcinogenicity and Toxicity <strong>of</strong> Foreign <strong>Compounds</strong>, Orlando, FL: Academic Press. BOND, J.A., 1989, Review <strong>of</strong> the toxicology <strong>of</strong> styrene, CRC Crit. Rev. Toxicol 19, 227–49. DANKOVIC, D.A. and BAILER, A.J., 1994, The impact <strong>of</strong> exercise and intersubject variability on dose estimates for dichloromethane derived from a physiologically based pharmacokinetic model, Fund. Appl. Toxicol, 22, 20–5. ECETOC, 1992, Technical report No. 52, Styrene toxicology. Investigations on the potential for carcinogenicity, Brussels: Ecetoc.
G.J.MULDER 43 GREEN, T., PROVAN, W.M., COLLINGE, D.C. and GUEST, A.E., 1988, Macro molecular interactions <strong>of</strong> inhaled methylene chloride in rats and mice, Toxicol. Appl. Pharmacol, 93, 1–10. GUENGERICH, F.R., 1992, Roles <strong>of</strong> the vinylchloride oxidation products 1chlorooxirane and 2-chloroacetaldehyde in the in vitro formation <strong>of</strong> etheno adducts <strong>of</strong> nucleic acid bases, Chem. Res. Toxicol, 5, 2–5. INSKEEP, P.B., KOGA, N.K., CMARIK, J.L. and GUENGERICH, F.P., 1986, Covalent binding <strong>of</strong> 1,2-dihaloalkanes to DNA, Cancer Res., 46, 2839–44. KADLUBAR, F.F., UNRUH, L.E., FLAMMANG, T.J., SPARKS, D., MITCHUM, R.K. and MULDER, G.J., 1981, Alteration <strong>of</strong> urinary levels <strong>of</strong> the carcinogen, N-hydroxy-2-naphthylamine, and its N-glucuronide in the rat by control <strong>of</strong> urinary pH, inhibition <strong>of</strong> metabolic sulfation, and changes in biliary excretion, Chem.-Biol. Interact. 33, 129–47. KLINE, S.A., ROBERTSON, J.F., GROTZ, V.L., GOLDSTEIN, B.D. and WITZ, G., 1993, Identification <strong>of</strong> 6-hydroxy-trans,trans-2,4-hexadienoic acid, a novel ring-opened urinary metabolite <strong>of</strong> benzene, Environm. Hlth Perspect., 101, 310–12. MULDER, G.J., 1992, Pharmacological effects <strong>of</strong> drug conjugates: is morphine 6glucuronide an exception? Trends Pharmacol. Sci., 13, 302–4. MULDER, G.J. and LE, C.T., 1988, A rapid simple in vitro screening test to detect reactive intermediates <strong>of</strong> xenobiotics. Toxicol. In Vitro, 2, 225–30. POHL, L.R., GEORGE, J.W. and SATOH, H., 1984, Strain and sex differences in chlor<strong>of</strong>orm-induced nephrotoxicity. Drug Metab. Disposit., 12, 304–7. REITZ, R.H., MENDRALA, A.L. and GUENGERICH, F.P., 1989, In vitro metabo-lism <strong>of</strong> methylene chloride in human and animal tissues, Toxicol. Appl. Pharmacol, 97, 230–46. REITZ, R.H., MENDRALA, A.L. and CONOLLY, R.B., 1990, Estimating the risk <strong>of</strong> liver cancer associated with human exposures to chlor<strong>of</strong>orm using PbPK modeling, Toxicol. Appl. Pharmacol., 105, 443–59. SWAEN, G.M.H. et al., 1987, A scientific basis for the risk assessment <strong>of</strong> vinyl chloride, Regul. Toxicol. Pharmacol, 7, 120–7. SWAEN, G.M.H. et al., 1989, Carcinogenic risk assessment <strong>of</strong> benzene in outdoor air, Regul. Toxicol. Pharmacol., 9, 175–85. WACHSMAN, J.T., BRISTOL, D.W., SPALDING, J., SHELBY, M. and TENNANT, R.W., 1993, Predicting chemical carcinogenesis in rodents, Environm. Hlth Perspect., 101, 444–5. WANG, X.P., CHAN, H.M., GOYER, R.A. and CHERIAN, M.G., 1993, Nephrotoxicity <strong>of</strong> repeated injections <strong>of</strong> cadmium-metallothionein in rats, Toxicol. Appl. Pharmacol., 119, 11–16.
- Page 2 and 3:
Toxicology of Industrial Compounds
- Page 4 and 5:
This edition published in the Taylo
- Page 6 and 7: 8. Pulmonary Toxicity Studies with
- Page 8 and 9: Preface A large number of chemical
- Page 10 and 11: Contributors May Akrawi Department
- Page 12 and 13: Beverly M.Kulig TNO Toxicology, Dep
- Page 14 and 15: Richard A.Versen Schuller MTC, Heal
- Page 16 and 17: 1 Biomonitoring and Absorption of I
- Page 18 and 19: 4 BIOMONITORING AND ABSORPTION OF I
- Page 20 and 21: 6 BIOMONITORING AND ABSORPTION OF I
- Page 22 and 23: 8 BIOMONITORING AND ABSORPTION OF I
- Page 24 and 25: 10 BIOMONITORING AND ABSORPTION OF
- Page 26 and 27: 2 Toxicokinetics and Biodisposition
- Page 28 and 29: 14 TOXICOKINETICS AND BIODISPOSITIO
- Page 30 and 31: 16 TOXICOKINETICS AND BIODISPOSITIO
- Page 32 and 33: 18 TOXICOKINETICS AND BIODISPOSITIO
- Page 34 and 35: 20 TOXICOKINETICS AND BIODISPOSITIO
- Page 36 and 37: 22 TOXICOKINETICS AND BIODISPOSITIO
- Page 38 and 39: 24 TOXICOKINETICS AND BIODISPOSITIO
- Page 40 and 41: 26 TOXICOKINETICS AND BIODISPOSITIO
- Page 42 and 43: 28 TOXICOKINETICS AND BIODISPOSITIO
- Page 44 and 45: 30 TOXICOKINETICS AND BIODISPOSITIO
- Page 46 and 47: 32 TOXICOKINETICS AND BIODISPOSITIO
- Page 48 and 49: 34 TOXICOKINETICS AND BIODISPOSITIO
- Page 50 and 51: 3 Metabolic Activation of Industria
- Page 52 and 53: 38 METABOLIC ACTIVATION OF INDUSTRI
- Page 54 and 55: 40 METABOLIC ACTIVATION OF INDUSTRI
- Page 58 and 59: 4 Sizing up the Problem of Exposure
- Page 60 and 61: 46 SIZING UP THE PROBLEM OF EXPOSUR
- Page 62 and 63: 48 SIZING UP THE PROBLEM OF EXPOSUR
- Page 64 and 65: 50 SIZING UP THE PROBLEM OF EXPOSUR
- Page 66 and 67: 52 SIZING UP THE PROBLEM OF EXPOSUR
- Page 68 and 69: 54 SIZING UP THE PROBLEM OF EXPOSUR
- Page 70 and 71: 56 SIZING UP THE PROBLEM OF EXPOSUR
- Page 72 and 73: 58 SIZING UP THE PROBLEM OF EXPOSUR
- Page 74 and 75: 5 Metabolism of Reactive Chemicals
- Page 76 and 77: 62 METABOLISM OF REACTIVE CHEMICALS
- Page 78 and 79: 64 METABOLISM OF REACTIVE CHEMICALS
- Page 80 and 81: 66 METABOLISM OF REACTIVE CHEMICALS
- Page 82 and 83: 68 METABOLISM OF REACTIVE CHEMICALS
- Page 84 and 85: 70 METABOLISM OF REACTIVE CHEMICALS
- Page 86 and 87: 6 Methods for the Determination of
- Page 88 and 89: 74 METHODS FOR THE DETERMINATION OF
- Page 90 and 91: 76 METHODS FOR THE DETERMINATION OF
- Page 92 and 93: 78 METHODS FOR THE DETERMINATION OF
- Page 94 and 95: 80 METHODS FOR THE DETERMINATION OF
- Page 96 and 97: 82 METHODS FOR THE DETERMINATION OF
- Page 98 and 99: 84 METHODS FOR THE DETERMINATION OF
- Page 100 and 101: 86 METHODS FOR THE DETERMINATION OF
- Page 102 and 103: 88 METHODS FOR THE DETERMINATION OF
- Page 104 and 105: PART THREE Pulmonary toxicology of
- Page 106 and 107:
92 CARCINOGENIC POTENTIAL OF MAN-MA
- Page 108 and 109:
94 CARCINOGENIC POTENTIAL OF MAN-MA
- Page 110 and 111:
96 CARCINOGENIC POTENTIAL OF MAN-MA
- Page 112 and 113:
98 CARCINOGENIC POTENTIAL OF MAN-MA
- Page 114 and 115:
100 CARCINOGENIC POTENTIAL OF MAN-M
- Page 116 and 117:
102 CARCINOGENIC POTENTIAL OF MAN-M
- Page 118 and 119:
104 CARCINOGENIC POTENTIAL OF MAN-M
- Page 120 and 121:
106 CARCINOGENIC POTENTIAL OF MAN-M
- Page 122 and 123:
108 CARCINOGENIC POTENTIAL OF MAN-M
- Page 124 and 125:
110 CARCINOGENIC POTENTIAL OF MAN-M
- Page 126 and 127:
112 CARCINOGENIC POTENTIAL OF MAN-M
- Page 128 and 129:
114 CARCINOGENIC POTENTIAL OF MAN-M
- Page 130 and 131:
116 CARCINOGENIC POTENTIAL OF MAN-M
- Page 132 and 133:
118 PULMONARY TOXICITY STUDIES WITH
- Page 134 and 135:
120 PULMONARY TOXICITY STUDIES WITH
- Page 136 and 137:
122 PULMONARY TOXICITY STUDIES WITH
- Page 138 and 139:
124 PULMONARY TOXICITY STUDIES WITH
- Page 140 and 141:
126 PULMONARY TOXICITY STUDIES WITH
- Page 142 and 143:
128 PULMONARY TOXICITY STUDIES WITH
- Page 144 and 145:
130 PULMONARY HYPERREACTIVITY TO IN
- Page 146 and 147:
132 PULMONARY HYPERREACTIVITY TO IN
- Page 148 and 149:
134 PULMONARY HYPERREACTIVITY TO IN
- Page 150 and 151:
136 PULMONARY HYPERREACTIVITY TO IN
- Page 152 and 153:
10 Mechanisms of Pulmonary Sensitiz
- Page 154 and 155:
140 MECHANISMS OF PULMONARY SENSITI
- Page 156 and 157:
142 MECHANISMS OF PULMONARY SENSITI
- Page 158 and 159:
144 MECHANISMS OF PULMONARY SENSITI
- Page 160 and 161:
146 MECHANISMS OF PULMONARY SENSITI
- Page 162 and 163:
148 MECHANISMS OF PULMONARY SENSITI
- Page 164 and 165:
150 OCCUPATIONAL ASTHMA INDUCED BY
- Page 166 and 167:
152 OCCUPATIONAL ASTHMA INDUCED BY
- Page 168 and 169:
154 OCCUPATIONAL ASTHMA INDUCED BY
- Page 170 and 171:
156 OCCUPATIONAL ASTHMA INDUCED BY
- Page 172 and 173:
12 Biomarkers and Risk Assessment K
- Page 174 and 175:
160 BIOMARKERS AND RISK ASSESSMENT
- Page 176 and 177:
162 BIOMARKERS AND RISK ASSESSMENT
- Page 178 and 179:
164 BIOMARKERS AND RISK ASSESSMENT
- Page 180 and 181:
166 BIOMARKERS AND RISK ASSESSMENT
- Page 182 and 183:
168 EXTRAPOLATION OF TOXICITY DATA
- Page 184 and 185:
170 EXTRAPOLATION OF TOXICITY DATA
- Page 186 and 187:
172 EXTRAPOLATION OF TOXICITY DATA
- Page 188 and 189:
174 EXTRAPOLATION OF TOXICITY DATA
- Page 190 and 191:
176 EXTRAPOLATION OF TOXICITY DATA
- Page 192 and 193:
178 EXTRAPOLATION OF TOXICITY DATA
- Page 194 and 195:
14 Molecular Approaches to Assess C
- Page 196 and 197:
182 MOLECULAR APPROACHES TO ASSESS
- Page 198 and 199:
184 MOLECULAR APPROACHES TO ASSESS
- Page 200 and 201:
186 MOLECULAR APPROACHES TO ASSESS
- Page 202 and 203:
188 MOLECULAR APPROACHES TO ASSESS
- Page 204 and 205:
190 MOLECULAR APPROACHES TO ASSESS
- Page 206 and 207:
192 MOLECULAR APPROACHES TO ASSESS
- Page 208 and 209:
194 MOLECULAR APPROACHES TO ASSESS
- Page 210 and 211:
196 MOLECULAR APPROACHES TO ASSESS
- Page 212 and 213:
198 EVALUATION OF TOXICITY TO THE I
- Page 214 and 215:
200 EVALUATION OF TOXICITY TO THE I
- Page 216 and 217:
202 EVALUATION OF TOXICITY TO THE I
- Page 218 and 219:
204 EVALUATION OF TOXICITY TO THE I
- Page 220 and 221:
206 EVALUATION OF TOXICITY TO THE I
- Page 222 and 223:
208 USE OF LONG-TERM CULTURES OF HE
- Page 224 and 225:
210 USE OF LONG-TERM CULTURES OF HE
- Page 226 and 227:
212 USE OF LONG-TERM CULTURES OF HE
- Page 228 and 229:
214 USE OF LONG-TERM CULTURES OF HE
- Page 230 and 231:
216 USE OF LONG-TERM CULTURES OF HE
- Page 232 and 233:
218 USE OF LONG-TERM CULTURES OF HE
- Page 234 and 235:
220 USE OF LONG-TERM CULTURES OF HE
- Page 236 and 237:
PART FIVE Mechanisms of toxicity of
- Page 238 and 239:
224 PEROXISOME PROLIFERATION normal
- Page 240 and 241:
226 PEROXISOME PROLIFERATION demons
- Page 242 and 243:
228 PEROXISOME PROLIFERATION Specie
- Page 244 and 245:
230 PEROXISOME PROLIFERATION intend
- Page 246 and 247:
232 PEROXISOME PROLIFERATION BENTLE
- Page 248 and 249:
234 PEROXISOME PROLIFERATION KRAUPP
- Page 250 and 251:
236 PEROXISOME PROLIFERATION POPP,
- Page 252 and 253:
18 Neurotoxicity Testing of Industr
- Page 254 and 255:
240 NEUROTOXICITY TESTING OF INDUST
- Page 256 and 257:
242 NEUROTOXICITY TESTING OF INDUST
- Page 258 and 259:
244 NEUROTOXICITY TESTING OF INDUST
- Page 260 and 261:
246 NEUROTOXICITY TESTING OF INDUST
- Page 262 and 263:
248 NEUROTOXICITY TESTING OF INDUST
- Page 264 and 265:
250 NEUROTOXICITY TESTING OF INDUST
- Page 266 and 267:
252 NEUROTOXICITY TESTING OF INDUST
- Page 268 and 269:
254 NEUROTOXICITY TESTING OF INDUST
- Page 270 and 271:
256 ENDOCRINE TOXICOLOGY OF THE THY
- Page 272 and 273:
258 ENDOCRINE TOXICOLOGY OF THE THY
- Page 274 and 275:
260 ENDOCRINE TOXICOLOGY OF THE THY
- Page 276 and 277:
262 ENDOCRINE TOXICOLOGY OF THE THY
- Page 278 and 279:
264 ENDOCRINE TOXICOLOGY OF THE THY
- Page 280 and 281:
266 ENDOCRINE TOXICOLOGY OF THE THY
- Page 282 and 283:
268 ENDOCRINE TOXICOLOGY OF THE THY
- Page 284 and 285:
270 ENDOCRINE TOXICOLOGY OF THE THY
- Page 286 and 287:
272 ENDOCRINE TOXICOLOGY OF THE THY
- Page 288 and 289:
274 ENDOCRINE TOXICOLOGY OF THE THY
- Page 290 and 291:
276 ENDOCRINE TOXICOLOGY OF THE THY
- Page 292 and 293:
278 ENDOCRINE TOXICOLOGY OF THE THY
- Page 294 and 295:
20 Testing and Evaluation for Repro
- Page 296 and 297:
282 TESTING AND EVALUATION FOR REPR
- Page 298 and 299:
284 TESTING AND EVALUATION FOR REPR
- Page 300 and 301:
286 TESTING AND EVALUATION FOR REPR
- Page 302 and 303:
288 TESTING AND EVALUATION FOR REPR
- Page 304 and 305:
290 TESTING AND EVALUATION FOR REPR
- Page 306 and 307:
292 TESTING AND EVALUATION FOR REPR
- Page 308 and 309:
294 TESTING AND EVALUATION FOR REPR
- Page 310 and 311:
296 TESTING AND EVALUATION FOR REPR
- Page 312 and 313:
298 TESTING AND EVALUATION FOR REPR
- Page 314 and 315:
PART SIX Toxicity of selected class
- Page 316 and 317:
302 SPECIAL POINTS IN THE TOXICITY
- Page 318 and 319:
304 SPECIAL POINTS IN THE TOXICITY
- Page 320 and 321:
306 SPECIAL POINTS IN THE TOXICITY
- Page 322 and 323:
308 SPECIAL POINTS IN THE TOXICITY
- Page 324 and 325:
310 TOXICOLOGY OF TEXTILE CHEMICALS
- Page 326 and 327:
312 TOXICOLOGY OF TEXTILE CHEMICALS
- Page 328 and 329:
314 TOXICOLOGY OF TEXTILE CHEMICALS
- Page 330 and 331:
316 TOXICOLOGY OF TEXTILE CHEMICALS
- Page 332 and 333:
318 ANTIOXIDANTS AND LIGHT STABILIS
- Page 334 and 335:
320 ANTIOXIDANTS AND LIGHT STABILIS
- Page 336 and 337:
322 ANTIOXIDANTS AND LIGHT STABILIS
- Page 338 and 339:
324 ANTIOXIDANTS AND LIGHT STABILIS
- Page 340 and 341:
326 ANTIOXIDANTS AND LIGHT STABILIS
- Page 342 and 343:
328 ANTIOXIDANTS AND LIGHT STABILIS
- Page 344 and 345:
330 ANTIOXIDANTS AND LIGHT STABILIS
- Page 346 and 347:
332 ANTIOXIDANTS AND LIGHT STABILIS
- Page 348 and 349:
334 ANTIOXIDANTS AND LIGHT STABILIS
- Page 350 and 351:
336 ANTIOXIDANTS AND LIGHT STABILIS
- Page 352 and 353:
338 ANTIOXIDANTS AND LIGHT STABILIS
- Page 354 and 355:
340 TOXICOLOGY OF SURFACTANTS Inter
- Page 356 and 357:
342 TOXICOLOGY OF SURFACTANTS Figur
- Page 358 and 359:
344 TOXICOLOGY OF SURFACTANTS probl
- Page 360 and 361:
346 TOXICOLOGY OF SURFACTANTS nonio
- Page 362 and 363:
348 TOXICOLOGY OF SURFACTANTS and t
- Page 364 and 365:
350 TOXICOLOGY OF SURFACTANTS long-
- Page 366 and 367:
352 TOXICOLOGY OF SURFACTANTS COULS
- Page 368 and 369:
354
- Page 370 and 371:
25 Low Dose of a Genotoxic Carcinog
- Page 372 and 373:
358 CARCINOGENESIS AT LOW DOSE Tabl
- Page 374 and 375:
360 CARCINOGENESIS AT LOW DOSE year
- Page 376 and 377:
26 Controversial Mechanistic and Re
- Page 378 and 379:
364 CONTROVERSIAL ISSUES IN SAFETY
- Page 380 and 381:
366 CONTROVERSIAL ISSUES IN SAFETY
- Page 382 and 383:
368 CONTROVERSIAL ISSUES IN SAFETY
- Page 384 and 385:
370 CONTROVERSIAL ISSUES IN SAFETY
- Page 386 and 387:
372 CONTROVERSIAL ISSUES IN SAFETY
- Page 388 and 389:
374 INDEX 2-bromo-glutathionyl 64 B
- Page 390 and 391:
376 INDEX Gas chromatography/mass s
- Page 392 and 393:
378 INDEX mRNA analysis 211 Mutagen
- Page 394 and 395:
380 INDEX Surfactants 338-55 acute